Dysregulation of microRNAs and target genes networks in human abdominal aortic aneurysm tissues

Authors: Neire Niara Ferreira de Araujo aff001;  Hui Tzu Lin-Wang aff002;  Juliana de Freitas Germano aff003;  Pedro Silvio Farsky aff001;  Andre Feldman aff001;  Fabio Henrique Rossi aff004;  Nilo Mitsuru Izukawa aff004;  Maria de Lourdes Higuchi aff005;  Felicio Savioli Neto aff001;  Mario Hiroyuki Hirata aff002;  Marcelo Chiara Bertolami aff001
Authors place of work: Department of Clinical Cardiology, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil aff001;  Laboratory of Molecular Investigation in Cardiology, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil aff002;  School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil aff003;  Department of Vascular Surgery, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil aff004;  Laboratory of Cardiac Pathology, Heart Institute, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil aff005
Published in the journal: PLoS ONE 14(9)
Category: Research Article
doi: 10.1371/journal.pone.0222782



Abdominal aortic aneurysm (AAA) is a pathological enlargement of infrarenal aorta close to the aortic bifurcation, and it is an important cause of mortality in the elderly. Therefore, the biomarker identification for early diagnosis is of great interest for clinical benefit. It is known that microRNAs (miRNAs) have important roles via target genes regulation in many diseases. This study aimed to identify miRNAs and their target genes involved in the pathogenesis of AAA.


Tissue samples were obtained from patients who underwent AAA surgery and from organ donors (control group). Quantitative PCR Array was applied to assess 84 genes and 384 miRNAs aiming to identify differentially expressed targets (AAA n = 6, control n = 6), followed by validation in a new cohort (AAA n = 18, control n = 6) by regular qPCR. The functional interaction between validated miRNAs and target genes was performed by the Ingenuity Pathway Analysis (IPA) software.


The screening cohort assessed by PCR array identified 10 genes and 59 miRNAs differentially expressed (≥2-fold change, p<0.05). Among these, IPA identified 5 genes and 9 miRNAs with paired interaction. ALOX5, PTGIS, CX3CL1 genes, and miR-193a-3p, 125b-5p, 150-5p maintained a statistical significance in the validation cohort. IPA analysis based on the validated genes and miRNAs revealed that eicosanoid and metalloproteinase/TIMP synthesis are potentially involved in AAA.


Paired interactions of differentially expressed ALOX5, PTGIS, CX3CL1 genes, and miR-193b-3p, 125b-5p, 150-5p revealed a potentially significant role of the eicosanoid synthesis and metalloproteinase/TIMP pathways in the AAA pathogenesis.


Biology and life sciences – Biochemistry – Nucleic acids – RNA – Non-coding RNA – Natural antisense transcripts – MicroRNAs – Neurochemistry – Neurochemicals – Eicosanoids – Proteins – Elastin – Genetics – Gene expression – Gene regulation – Molecular biology – Molecular biology techniques – Artificial gene amplification and extension – Polymerase chain reaction – Neuroscience – Research and analysis methods – Medicine and health sciences – Vascular medicine – Vascular diseases – Aneurysms – Pathology and laboratory medicine – Pathogenesis


Abdominal aortic aneurysm (AAA) is a pathological enlargement of infrarenal aorta close to the aortic bifurcation, and it is an important cause of mortality in the elderly. The AAA incidence in individuals older than 60 years of age is higher in men than in women; 5% vs. 1%, respectively [1,2]. Smoking is the main risk factor for the expansion of AAA [3] and other risks include age, male gender, lower HDL cholesterol levels, and genetic susceptibility [4,5].

Ultrasonography (US) is routinely used to diagnose and monitoring AAA, with sensitivity and specificity close to 100% in the late stage of the disease; most cases are detected by chance during routine abdominal US [6,7]. Aortic diameter larger than 3 cm is suggestive of AAA; aortic diameter larger than 5 cm shows worse outcome, requiring intense monitoring [8] and treatment to reduce aortic inflammation, proteolysis, and support vascular smooth muscle cell recovery [6]. The annual rupture risk increases with aortic enlargement, reaching 30% in AAA larger than 7 cm [9]. In these cases, surgical repair is advised; however, preoperative risk also has to be taken into consideration.

The mechanisms underlying AAA are complex and not completely understood. However, some studies suggest that AAA development is mainly associated with increased biomechanical stress, proteolytic degeneration of elastin and collagen in the aortic wall, inflammation processes, genetic factors, and immune responses [10,11]. Some molecules, such as CCL22 [12] and CTLA4 [13] are suggested as biomarkers for AAA diagnosis.

Adequate regulation of gene expression is critical for all cellular processes and its dysregulation may contribute to disease. Gene expression can be regulated at the post-transcriptional level by small non-coding RNAs, known as microRNAs (miRNA), which are short, single-stranded RNAs (approximately 22 bp) that control mRNA stability or translational repression via base pairing with regions within the 3' untranslated region of the target RNA [14]. The miRNAs are found not only inside the cells, but also in biological fluids such as serum, plasma, urine, and saliva [15], and can be delivered into different tissues through vesicles and lipoprotein transport [16]. The role and implications of miRNAs in animal models and their relevance to human AAA have also been discussed [17]. The circulating miR-455-3p has been suggested as a promising biomarker for the early diagnosis of AAA [18]. However, the role of miRNAs in AAA development remains to be clarified.

To date, the available treatments for AAA are surgical or interventional using different kinds of prosthesis, and new targets need to be identified in order to bring alternatives to diagnosis and therapy. Here, we analyzed miRNA and mRNA profiles of human AAA tissues and applied miRNA-mRNA interactions to predict molecular pathways that may outline potential targets for therapeutic approaches to control AAA progression.

Materials and methods

Ethics statement

This study was approved by the ethics committee of the Dante Pazzanese Institute of Cardiology in Sao Paulo, Brazil (number 1470/2014). Each participant signed an informed consent after receiving a verbal explanation of the study. Patients who had cognitive deficit were not enrolled. The donation term was signed by responsible relatives in accordance with the Brazilian laws for organ and tissue donation.

Abdominal aortic tissues samples

Abdominal aortic tissues were obtained from patients undergoing AAA repair surgery and from brain-dead but heart beating organ donors. The characteristics of the screening and validation cohort are shown in Table 1. The excised segments of the abdominal aorta were collected in RNAlater® stabilization solution (Ambion Inc., MN, USA) and stored at -20 °C until assayed.

Tab. 1.

Biodemographic characteristics of screening and validation cohort.

<h2>Biodemographic characteristics of screening and validation cohort.</h2>

To check if the tissues from organ donors were adequate to use as a control, we applied Verhoeff´s histological staining to assess elastin, an extracellular matrix protein. The image was acquired by a Scanscope CS system unit (Aperio Technologies Inc., CA, USA), with an Olympus UPlanSApo objective lens, with specifications of 20x magnification power and 0.75 numerical aperture attached to the scanner. Images were analyzed using the Aperio program ImageScope View software (Aperio Technologies, Inc., CA, USA). Results were reported as the positive staining percentage area per total tissue area.

RNA extraction and qPCR array analysis

Tissue samples from AAA (n = 6) and control group (n = 6) were randomly selected for qPCR array analysis.

To obtain mRNA, 20 mg of aortic tissues containing all layers were firstly homogenized by TissueRuptor® (Qiagen, GmbH, Hilden, Germany), followed by extraction using RNeasy Microarray Tissue Mini Kit (Qiagen, GmbH, Hilden, Germany), according to manufacturer recommendations. RNA quantification was determined using a Qubit® spectrophotometer system (Life Technologies, Foster City, CA, USA) and sample quality was assessed by Agilent Technologies 2200 Tape Station (Agilent Technologies Inc., USA). All samples had RNA integrity number (RIN) higher than eight, therefore, they were suitable for downstream processing.

The RT2 First Strand Kit (Qiagen, GmbH, Hilden, Germany) was used for cDNA synthesis and quality control was performed using RT2 RNA QC RT2 Profiler PCR Array plates (PAHS-999Z), which looked out for the presence of reverse transcription inhibitors, PCR amplification efficiency, and DNA contamination.

The screening of candidate genes involved in AAA pathogenesis was performed by the RotorGene® Real-Time PCR system (Qiagen, Hilden, Germany) using RT2 Profiler PCR Arrays (PAHS-015Z, Qiagen, Hilden, Germany). This array includes 84 genes involved in angiogenesis, vasoconstriction, vasodilation, inflammatory response, apoptosis, cell adhesion molecules, coagulation, and platelet activation.

The PCR cycling condition was set as follows: 1 cycle at 95 °C for 10 min, 40 cycles at 95 °C for 15 s, and 60 °C for 30 s. The Qiagen web-based PCR array data analysis software was applied to obtain fold change of gene expression. Genes showing ≥2-fold change and p-value <0.05 were considered as differentially expressed. A cycle of threshold (Ct) value higher than 35 was considered as no amplification.

MicroRNA extraction and qPCR array analysis

The total RNA including miRNAs were isolated using RNeasy Fibrous Tissue Mini Kit (Qiagen, GmbH, Germany) according to the protocol. RNA was quantified using the RNA assay kit in Qubit® spectrophotometer. All samples showed RIN (RNA integrity number) >8.0 and were suitable for downstream processing. An input of 800ng of total RNA was used to prepare the cDNA following the miScript II RT protocol (Qiagen, Hilden, Germany). The quality control of cDNA samples was assessed by miScript miRNA QC PCR plates (MIHS-989ZE, Qiagen, Hilden, Germany). Quantitative PCR was performed according to manual instructions in QuantiStudio® 12k Flex Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA) using Human miFinder 384HC miScript miRNA PCR Arrays (Qiagen, Hilden, Germany). The PCR cycling conditions were set as follows: 1 cycle at 95 °C for 15 min; 40 cycles of 3 step cycling: 94 °C for 15 s, 55 °C for 30 s and 70 °C for 30 s. The Ct values were submitted to the Qiagen web-based PCR array data analysis software and the 2-ΔΔCt formula was used to compare miRNA expression between groups. The global mean normalization method was used to normalize the miRNA Cts [19]. The miRNAs showing ≥ 2-fold change and p-value < 0.05 were considered as differentially expressed. Ct values higher than 35 were not included in the analysis.

Ingenuity Pathway Analysis® (IPA)

Functional analysis was performed by IPA® software (Qiagen, Hilden, Germany). Interactions between differentially expressed miRNAs and target genes were assessed by opposite pairwise analysis (Table 2), and Molecular Activation Prediction (MAP) analysis was applied to predict molecular activation or inhibition that may be involved in AAA pathogenesis. New pathway analysis was performed to investigate the interaction between the validated genes and miRNAs. Intermediary molecules were added to the pathway to clarify the link between these miRNAs and their target genes and explain the relevant roles in the AAA context.

Tab. 2.

Differently expressed miRNA was paired up with the respective target gene by IPA pairing analysis.

<h2>Differently expressed miRNA was paired up with the respective target gene by IPA pairing analysis.</h2>

Validation of paired expressed genes and miRNAs

The validation cohort consisted of other samples different from the ones employed for screening, 18 AAA samples, and 6 organ donor control.

All samples were tested for miRNAs and genes that showed paired interactions in the paired expression analysis (Table 2). The miRNA and mRNA analysis followed the same steps described above using the RT2 qPCR primer assays for gene expression and miScript primer assays for miRNA expression. Assays used for this proposal were: ALOX5 (#PPH2590G), CX3CL1 (#PPH689C), PTGIS (#PPH2582A), FN1 (#PPH143B), AGTR1 (#PPH2362F), TIMP1 (#PPH00771C), miR-1207-5p (#MS14189), miR-125b-5p (#MS6629), miR-150-5p (#MS3577), miR-16-5p (#MS31493), miR-193b-3p (#MS31549), miR-34c-5p (#MS3332). The average expression of three reference genes: ACTB (#PPH73G), B2M (#PPH1094E) and GAPDH (#PPH150F) were applied for normalization of the gene expression, and in case of miRNAs expression, the average expression of SNORD61 (#MS33705), SNORD68 (#MS33712) and RNU6-6p (#MS33740) was applied for normalization.

The relative expression was calculated by the 2-ΔΔCt formula [20], and results were reported as fold change.

Statistical analysis

The biodemographic data was reported as average and standard deviation or as count and percentage. The t-test was used to compare numerical variables from the biodemographic data and the likelihood ratio or Fisher’s exact test was used to compare categorical variables. The elastin detected by immunohistochemical staining, as well as the miRNA and gene expression were analyzed by a Mann-Whitney U test for non-parametric data and reported as median, 25th and 75th percentiles. Differences were considered statistically significant when p < 0.05.


Biodemographic data and sample characteristics

As expected, patients from the AAA group were older than the donors. Also, the AAA group showed a higher frequency of male sex, hypertension, dyslipidemia, diabetes and family history of coronary artery disease (Table 1).

The aneurysm from the AAA group achieved a 5.9 cm diameter on average while the control group had an abdominal aortic diameter smaller than 3.0 cm detected by observational analysis only. Comparative microscopic analysis revealed that AAA tissues had a significant decrease in elastin fiber. The 25th and 75th percentile of elastin detected by Verhoeff´s staining was 1.0% and 9.3% in AAA compared to 3.1% and 24.6% in the control group (p < 0.001), respectively.

Gene and miRNA qPCR array analysis

Ten out of 84 genes analyzed by RT-qPCR were differentially expressed in the AAA group (n = 6) when compared to the control group (n = 6). Six genes (PTGIS, CX3CL1, ITGB1, COL18A1, FN1, and AGTR1) were significantly downregulated and four other genes (SPHK1, TYMP, ALOX5, HIF1A) were significantly up-regulated (Table 3).

Tab. 3.

Differently expressed genes were identified by PCR array: AAA (n = 6) compared to organ donor control (n = 6).

<h2>Differently expressed genes were identified by PCR array: AAA (n = 6) compared to organ donor control (n = 6).</h2>

The expression analysis of 372 miRNAs by qPCR array showed a total of 59 differentially expressed miRNAs in the AAA group, from which 35 were down-regulated and 24 were up-regulated (Table 4).

Tab. 4.

Differently expressed miRNAs were identified by PCR array: AAA (n = 6) compared to organ donor control (n = 6).

<h2>Differently expressed miRNAs were identified by PCR array: AAA (n = 6) compared to organ donor control (n = 6).</h2>

Pathway analysis and qPCR validation

After identifying differentially expressed genes and miRNAs in the AAA group, the IPA software was used to recognize paired interactions between miRNAs and their target genes. Ten paired interactions were identified, which involved five differentially expressed genes and 9 miRNAs (Table 2).

Three out of six genes (FN1, TIMP1 and AGTR1) lost statistical relevance in the validation cohort, and, consequently, miRNAs associated with these genes (miR-182-5p, 200c-3p, and 34b-3p) did not follow validation. It is worth mentioning that 12 out of 18 samples had upregulation of TIMP1 ranging from 2 to 10 folds, even though statistical difference was not detected (Fig 1). Six miRNAs (miR-1207-5p, 125b-5p, 150-5p, 16-5p, 193b-3p and 34c-5p) showed paired interactions with genes and followed validation (Fig 2). Several samples showed miR-34c-5p Ct higher than 35, indicating no detectable expression. This miRNA was, therefore, excluded from the IPA representation on Fig 3. Although miRNAs 1207-5p and 16-5p are highly upregulated in array data, they showed no differences in the RT-PCR validation cohort and, were not included in the final IPA network.

<h2>Validation of gene expression by qPCR.</h2>
Fig. 1.

Validation of gene expression by qPCR.

The relative expression was calculated using the 2-ΔΔCt formula and Mann-Whitney test was performed to compare AAA (n = 18) and control groups (n = 6). The null hypothesis was rejected if the p-value was lower than 0.05.

<h2>Validation of microRNA expression by qPCR.</h2>
Fig. 2.

Validation of microRNA expression by qPCR.

The 2-ΔΔCt formula was applied to obtain relative expression and Mann-Whitney test was performed to compare AAA (n = 18) and control group (n = 6). The null hypothesis was rejected if the p-value waslower than 0.05.

<h2>Ingenuity Pathway Analysis (IPA) showed predicted interactions between validated miRNAs and their respective targets genes in abdominal aortic aneurysm.</h2>
Fig. 3.

Ingenuity Pathway Analysis (IPA) showed predicted interactions between validated miRNAs and their respective targets genes in abdominal aortic aneurysm.

Intermediary molecules are also showed in grey to clarify the connections of miRNAs and targets. The blue lines and molecules represent inhibition; orange lines and molecules represent activation; green represents miRNA down-regulation, and red represents miRNA up-regulation.

Through bioinformatic analysis, the results showed that eicosanoid synthesis (arachidonic acid and leukotriene) and metalloprotease/TIMP pathway are possibly the two main pathways involved in AAA pathogenesis that are directly regulated by differentially expressed miRNAs (Fig 3).


There is some literature showing the assess of miRNA or mRNA profile in AAA tissues [13,21]. However, the identified target substantially varies among studies, probably because different aortic fragments were assessed and distinct methods were employed. It is known that each aortic segment has a different embryonic origin and shows vascular smooth muscle diversity [22]; therefore, gene expression profile may also vary between aortic segments. In this study, we carefully obtained samples from the same aortic infra-renal fragments for both groups (AAA vs control). The AAA average aortic diameter was 5.9 cm, and there was a significant elastin fiber degradation associated with collagen down-expression, which characterizes chronic aneurysm. It is important to mention that this study was not designed to evaluate early AAA, once the tissues were obtained in a later stage, concomitant with the surgery. These results, combinedwith a serum miRNAs analysis [18], might be interesting to identify biomarkers for early AAA diagnosis.

According to Pahl and colleagues, target genes associated with apoptosis and activation of T cells are mainly involved in AAA. However, other vascular cells may also probably contribute to AAA pathogenesis [21]. For this proposal, firstly, we evaluated the expression of 84 genes associated with vascular function, and 372 most abundantly expressed miRNAs and best-characterized miRNAs in miRBase (www.miRBase.org). The screened genes and miRNAs were validated in a new cohort, consisted of 18 AAA samples. Surprisingly, two genes (FN1 and AGTR1) and three miRNAs (16-5p, 1207-5p, and 34c-5p) previously screened by PCR array lost the statistical significance in the validation test. Probably, the number of samples assessed in the array and the tissue heterogeneity contributed to the difference between these results, reinforcing the importance of validation in array approaches. Tavares et. al. showed that even though the biomechanical resistance of AAA varies with size or location of aorta, no histological or histochemical differences were detected in situ [23], hence the expression of gene and miRNA could be more sensitive for AAA monitoring.

Based on genes and miRNAs identified in the validation study, the IPA analysis showed two pathways associated with AAA: the eicosanoid synthesis pathway, with ALOX5 and PTGIS genes participation, and metalloprotease/TIMP pathway, which involves the CX3CL1 gene.

The role of ALOX5 in the eicosanoid synthesis pathway is well-established. This gene encodes the enzyme arachidonate 5-lipoxygenase which, in association with ALOX5AP protein [24], to catalyze the conversion of 5-HPETE to leukotriene A4 (LTA4), favor the proinflammatory leukotrienes biosynthesis [25] and increases the infiltration of immune cells through leukotriene B4 signaling [26]. ALOX5 also plays a key role in cathepsin K (CTSK) modulation [27], which is directly involved in AAA formation through mechanisms such as collagen turnover [28], T-cell proliferation, and smooth muscle cell apoptosis [29]. The regulation of ALOX5 transcript by miRNA-125b-5p was previously reported in several cell lines [30]. In this study, it was noted a down-regulation of miRNA-125b-5p and miR-193a-3p in AAA tissues leading to up-regulation of ALOX5 gene, which results in a leukotriene production increase and empowers aortic wall inflammation and injury.

Another gene involved in the eicosanoid synthesis pathway identified in our studyis PTGIS. This gene encodes prostaglandin I2 synthase and catalyzes prostacyclin (PGI2) synthesis from prostaglandin H2. PGI2 is widely distributed and predominantly found in vascular endothelial and smooth muscle cells and it has an inhibitory role in platelet aggregation and thrombus formation [31]. An imbalance of prostacyclin and its physiological antagonist thromboxane A2 (TXA2) contributes to the development of myocardial infarction, stroke, and atherosclerosis [32,33]. The frequencies of PTGIS (rs5602CC) and PTGS2 (rs20417CC) variants were significantly higher in patients with carotid plaque compared with patients without plaque, and are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients [34]. Our data suggests that up-regulation of miRNA-150-5p is possibly repressing PTGIS expression, which indirectly contributed to AAA progression through the leukotriene pathway. In this study, we did not assess PTGS2 expression; but it is known that PTGS2 is an induced form of prostaglandin-endoperoxide synthase, also known as cyclooxygenase, which is the key enzyme in prostaglandin biosynthesis. High-level tumor miR-21 expression may potentiate the PTGS2/PGE2 pathway and suppress antitumor immunity [35]. In AAA, miR-21 is usually upregulated [11,36], and modulation of miR-21 expression can limit AAA expansion through the inhibition of the expression of the phosphatase and tensin homolog (PTEN) protein [37]. In our array, the results showed that miR-21-3p is 2.6 folds higher in AAA than control, but the difference was not statistical significant (p = 0.210). Further study can clarify if miR-21 also regulates PTGS2/PGE2 pathway in AAA context.

The down-regulation of CX3CL1 (chemokine C-X3-C motif ligand 1) gene in AAA tissue was also observed in validated cohort. The protein codified by this gene inhibits tissue inhibitors of metalloproteinase (TIMP) and controls the turnover of matrix metalloproteinase (MMP). Recently, Ma et. al. described that the overexpression of miR-195 may induce the protein expression of MMP-2 and MMP-9 in AAA [38]. However, our study showed that miR-195 is equally expressed between AAA and control groups and,consequently, it was not included in the validation study. Through IPA® bioinformatic analysis, we observed down-regulation of CX3CL1 that favors TIMP1 gene activation. Furthermore, in validation cohort, 12 out of 18 samples showed upregulation of TIMP1 ranging from 2 to 10 folds. Together, TIMP1 and TIMP2 suppress the expression of MMP. These results corroborate the existing literature showing the increase of TIMP expression in AAA [39]. However, other authors reported opposite findings [40]. Probably different models used by these studies could explain these conflicting results. CX3CL1, also known as fractalkine, chemoattracts T cells and monocytes, and their adhesive and migratory functions by interacting with the receptor CX3CR1 on endothelial cells [41]. We could not validate the expression of miRNAs 16-5p and 1207-5p, but we do not discard the involvement of an additional miRNA not presented in the array panel in the down-regulation of CX3CL1 gene, or possible indirect regulation.

Our results identified SPHK1 as the most upregulated gene in AAA. Although no information in the literature supports the role of this gene in the development of AAA, it is known that SPHK1 regulates endothelial function [42], and could indirectly be involved in AAA pathogenesis.

Although it was not included in the validation step, it is worth mentioning that miRNA-23b-3p is by far the most expressed miRNA identified in this study; its expression in AAA tissue was almost 21-fold lower than that in the normal aorta. It has been shown that the miRNA-23b-3p plays a critical role in a wide range of biological processes, including angiogenesis [43] and positively regulating cardiac hypertrophy [44]. Its downregulation induces phenotypic switching of vascular smooth muscle cells from a low proliferative to a highly proliferative phenotype [45]. In this study, the IPA® bioinformatic tools did not identify targets among the differentially expressed genes in our PCR array. As previously mentioned, each miRNA can regulate one or more messenger RNA transcript and, conversely, a given mRNA can be regulated by more than one miRNA [14]. It is possible that miRNA-23b-3p is involved in aortic tissue maintenance; its low expression could be owing to high regulatory activity and catabolism.

Let-7g-3p is the most upregulated miRNA in our study, but didn’t show any direct interaction with the differentially expressed genes in IPA. In the human, the let-7 family is composed of 9 mature let-7 miRNAs highly conserved across different species, suggesting that they may play important roles in the biological processes of various organisms [46]. The tumor-suppressor role of let-7 miRNAs is known [47,48] and the new regulation functions has been described in different clinical situations.

It seems that the let-7 family has an extremely complex regulation network. Koh et. al. predicted that let-7 family miRNAs can regulate 50 genes and affect the downstream target HNF4A, which is a known endodermal differentiation marker [49]. Other study using a porcine shunt model of pulmonary hypertension showed both let-7d-3p and let-7g-3p miRNAs were upregulated, however, let-7f-2-3p was downregulated in endoarterial biopsy samples, suggesting that each let-7 family member has different regulation function [50], suggesting that let-7 family may participate in many molecular pathways and biologic processes simultaneously.

In AAA context, Kin et al. observed that the let-7 family members (let-7a, 7c, 7e and 7f) were significantly upregulated in the AAA tissue [36]. However, there is still no specific information about the association of let-7g and AAA. In this study, even though significant upregulation of let-7g-3p in AAA was observed, no differentially expressed gene showed paired interactions with this miRNA by IPA. Although no interactions between let-7 family and gene expression were found in our analysis, we believe that these miRNAs have an important role in the development of AAA through indirect regulations, which were not a focus of our validation and, consequently, not represented in our IPA network.

A major limitation of this study is the large diameter (5.9 cm) of AAA samples which corresponds to chronic AAA and may involve degeneration process. It is worth mentioning that tissue samples were only possible to obtain during surgery; therefore, the results may not be causal factors, but they might reflect chronic degenerative AAA. Three miRNAs identified in this study were not identified by another group which was searching for circulating miRNAs from patients with an AAA average diameter of 3.6 cm [51]. Probably, a different degree of AAA or biological material origin may have different miRNA profile.


In conclusion, dysregulation of miRNA-193b-3p, 125b-5p, 150-5p involved in the regulation of genes with a role in the eicosanoid synthesis such as ALOX5 and PTGIS, and metalloproteinase/TIMP pathway, such as CX3CL1 are potentially implicated in the AAA pathogenesis. The genes and miRNAs identified in this study could be important targets for clinical therapy and diagnosis of AAA.


1. Lederle F A; Johnson G R; Wilson SE. Abdominal aortic aneurysms in women. J Vasc Surg. 2001;34: 122–126. doi: 10.1067/mva.2001.115275 11436084

2. Pande RL, Beckman JA. Abdominal Aortic Aneurysm: Populations at Risk and How to Screen. Journal of Vascular and Interventional Radiology. 2008;19: S2–S8. doi: 10.1016/j.jvir.2008.03.010 18502382

3. Lindholt J., Heegaard NH., Vammen S, Fasting H, Henneberg E., Heickendorff L. Smoking, but not Lipids, Lipoprotein (a) and Antibodies Against Oxidised LDL, is Correlated to the Expansion of Abdominal Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2001;21: 51–56. doi: 10.1053/ejvs.2000.1262 11170878

4. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: Pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26: 2605–2613. doi: 10.1161/01.ATV.0000245819.32762.cb 16973970

5. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011;8: 92–102. doi: 10.1038/nrcardio.2010.180 21079638

6. Lederle FA, Walker JM, Reinke DB. Selective screening for abdominal aortic aneurysms with physical examination and ultrasound. Arch Intern Med. 1988;148: 1753–1756. 3041938

7. Lindholt JS, Vammen S, Juul S, Henneberg EW, Fasting H. The validity of ultrasonographic scanning as screening method for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 1999;17: 472–475. doi: 10.1053/ejvs.1999.0835 10375481

8. Reed WW, Hallett JW, Damiano MA, Ballard DJ. Learning from the last ultrasound. A population-based study of patients with abdominal aortic aneurysm. Arch Intern Med. 1997;157: 2064–2068. 9382661

9. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg. 2011;41: S1–S58. doi: 10.1016/j.ejvs.2010.09.011 21215940

10. Folkesson M, Kazi M, Zhu C, Silveira A, Hemdahl A-L, Hamsten A, et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemost. 2007;98: 427–433. 17721627

11. Iyer V, Rowbotham S, Biros E, Bingley J, Golledge J. A systematic review investigating the association of microRNAs with human abdominal aortic aneurysms. Atherosclerosis. 2017. pp. 78–89. doi: 10.1016/j.atherosclerosis.2017.03.010 28347473

12. Golledge J, Clancy P, Moran C, Biros E, Rush C, Walker P, et al. The novel association of the chemokine CCL22 with abdominal aortic aneurysm. Am J Pathol. American Society for Investigative Pathology; 2010;176: 2098–2106. doi: 10.2353/ajpath.2010.090416 20348247

13. Biros E, Moran CS, Wang Y, Walker PJ, Cardinal J, Golledge J. MicroRNA profiling in patients with abdominal aortic aneurysms: the significance of miR-155. Clin Sci. 2014;126: 795–803. doi: 10.1042/CS20130599 24283299

14. Olena AF, Patton JG. Genomic organization of microRNAs. JCell Physiol. 2014;222: 540–545.

15. Schöler N, Langer C, Döhner H, Buske C, Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol. 2010;38: 1126–1130. doi: 10.1016/j.exphem.2010.10.004 20977925

16. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285: 17442–17452. doi: 10.1074/jbc.M110.107821 20353945

17. Raffort J, Lareyre F, Clement M, Mallat Z. Micro-RNAs in abdominal aortic aneurysms: insights from animal models and relevance to human disease. Cardiovasc Res. 2016;110: 165–177. doi: 10.1093/cvr/cvw046 26965051

18. Zhang W, Shang T, Huang C, Yu T, Liu CC, Qiao T, et al. Plasma microRNAs serve as potential biomarkers for abdominal aortic aneurysm. Clin Biochem. Elsevier B.V.; 2015;48: 988–992. doi: 10.1016/j.clinbiochem.2015.04.016 25916817

19. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biology. 2009;10: R64. doi: 10.1186/gb-2009-10-6-r64 19531210

20. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nature Protocols. 2008;3: 1101–1108. doi: 10.1038/nprot.2008.73 18546601

21. Pahl MC, Derr K, Gäbel G, Hinterseher I, Elmore JR, Schworer CM, et al. MicroRNA expression signature in human abdominal aortic aneurysms. BMC Med Genomics. 2012;15: 25–37. doi: 10.1186/1755-8794-5-25 22704053

22. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol. 2007;27: 1248–1258. doi: 10.1161/ATVBAHA.107.141069 17379839

23. Tavares Monteiro JA, da Silva ES, Raghavan ML, Puech-Leão P, de Lourdes Higuchi M O J. Histologic, histochemical, and biomechanical properties of fragments isolated from the anterior wall of abdominal aortic aneurysms. J Vasc Surg. 2014;59: 1393–401. doi: 10.1016/j.jvs.2013.04.064 23891493

24. Gerstmeier J, Weinigel C, Rummler S, Rådmark O, Werz O, Garscha U. Time-resolved in situ assembly of the leukotriene-synthetic 5-lipoxygenase/5-lipoxygenase-activating protein complex in blood leukocytes. FASEB J. 2016;30: 1892–1900.

25. Zhao L, Moos MPW, Gräbner R, Pédrono F, Fan J, Kaiser B, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature medicine. 2004;10: 966–973. doi: 10.1038/nm1099 15322539

26. Bhamidipati CM, Whatling CA, Mehta GS, Meher AK, Hajzus VA, Su G, et al. 5-lipoxygenase pathway in experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2014;34: 2669–2678. doi: 10.1161/ATVBAHA.114.304016 25324573

27. Lee JM, Park H, Noh ALSM, Kang J-H, Chen L, Zheng T, et al. 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1. J Immunol. 2012;189: 5284–5292. doi: 10.4049/jimmunol.1003738 23109727

28. Abdul-Hussien H, Soekhoe RG V, Weber E, von der Thüsen JH, Kleemann R, Mulder A, et al. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol. 2007;170: 809–817. doi: 10.2353/ajpath.2007.060522 17322367

29. Sun J, Sukhova GK, Zhang J, Chen H, Sjöberg S, Libby P, et al. Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol. 2012;32: 15–23. doi: 10.1161/ATVBAHA.111.235002 21817099

30. Busch S, Auth E, Scholl F, Huenecke S, Koehl U, Suess B, et al. 5-lipoxygenase is a direct target of miR-19a-3p and miR-125b-5p. J Immunol. 2015;194: 1646–1653. doi: 10.4049/jimmunol.1402163 25589070

31. Weiss HJ, Turitto VT. Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood. 1979;53: 244–250. 367465

32. DeWitt DL, Day JS, Sonnenburg WK, Smith WL. Concentrations of prostaglandin endoperoxide synthase and prostaglandin I2 synthase in the endothelium and smooth muscle of bovine aorta. J Clin Invest. 1983;72: 1882–1888. doi: 10.1172/JCI111151 6417165

33. Ricciotti E, FitzGerald GA. Prostaglandins and Inflammation. Arterioscler Thromb Vasc Biol. 2011;31: 986–1000. doi: 10.1161/ATVBAHA.110.207449 21508345

34. Yi X, Lin J, Luo H, Wang C, Liu Y. Genetic variants of PTGS2, TXA2R and TXAS1 are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients. Bachschmid MM, editor. PLOS ONE. 2017;12: e0180704. doi: 10.1371/journal.pone.0180704 28704403

35. Mima K, Nishihara R, Yang J, Dou R, Masugi Y, Shi Y, et al. MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival. Clin Cancer Res. 2016;22: 3841–3848. doi: 10.1158/1078-0432.CCR-15-2173 26957558

36. Kin K, Miyagawa S, Fukushima S, Shirakawa Y, Torikai K, Shimamura K, et al. Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm. J Am Heart Assoc. 2012;1: e000745. doi: 10.1161/JAHA.112.000745 23316282

37. Maegdefessel L, Azuma J, Toh R, Deng A, Merk DR, Raiesdana A, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med. 2012;4: 122ra22. doi: 10.1126/scitranslmed.3003441 22357537

38. Ma X, Yao H, Yang Y, Jin L, Wang Y, Wu L, et al. miR-195 suppresses abdominal aortic aneurysm through the TNF-α/NF-κB and VEGF/PI3K/Akt pathway. Int J Mol Med. 2018;41: 2350–2358. doi: 10.3892/ijmm.2018.3426 29393364

39. Elmore JR, Keister BF, Franklin DP, Youkey JR, Carey DJ. Expression of Matrix Metalloproteinases and TIMPs in Human Abdominal Aortic Aneurysms. 1998;12: 221–228. doi: 10.1007/s100169900144 9588507

40. Defawe OD, Colige A, Lambert CA, Munaut C, Delvenne P, Lapière CM, et al. TIMP-2 and PAI-1 mRNA levels are lower in aneurysmal as compared to athero-occlusive abdominal aortas. Cardiovasc Res. 2003;60: 205–213. doi: 10.1016/s0008-6363(03)00513-3 14522424

41. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385: 640–644. doi: 10.1038/385640a0 9024663

42. Siedlinski M, Nosalski R, Szczepaniak P, Ludwig-Gałȩzowska AH, Mikołajczyk T, Filip M, et al. Vascular transcriptome profiling identifies Sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction. Sci Rep. 2017;7: 1–13.

43. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc Natl Acad Sci U S A. 2011;108: 8287–8292. doi: 10.1073/pnas.1105254108 21536891

44. Wang K, Lin Z-Q, Long B, Li J-H, Zhou J, Li P-F. Cardiac hypertrophy is positively regulated by microRNA miR-23a. J Biol Chem. 2012;287: 589–599. doi: 10.1074/jbc.M111.266940 22084234

45. Iaconetti C, De Rosa S, Polimeni A, Sorrentino S, Gareri C, Carino A, et al. Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res. 2015;107: 522–533. doi: 10.1093/cvr/cvv141 25994172

46. Lee H, Han S, Kwon CS, Lee D. Biogenesis and regulation of the let-7 miRNAs and their functional implications. Protein and Cell. Higher Education Press; 2016;7: 100–113. doi: 10.1007/s13238-015-0212-y 26399619

47. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7: 759–764. doi: 10.4161/cc.7.6.5834 18344688

48. Wang X, Cao L, Wang Yi, Wang X, Liu N, You Y. Regulation of let-7 and its target oncogenes (Review). Oncol Lett. 2012;3: 955–960. doi: 10.3892/ol.2012.609 22783372

49. Koh W, Sheng CT, Tan B, Lee QY, Kuznetsov V, Kiang LS, et al. Analysis of deep sequencing microRNA expression profile from human embryonic stem cells derived mesenchymal stem cells reveals possible role of let-7 microRNA family in downstream targeting of hepatic nuclear factor 4 alpha. BMC Genomics. 2010;11: 1–15.

50. Rothman A, Restrepo H, Sarukhanov V, Evans WN, Wiencek RG, Williams R, et al. Assessment of microRNA and gene dysregulation in pulmonary hypertension by endoarterial biopsy. Pulm Circ. 2017;7: 455–464. doi: 10.1177/2045893217704206 28597755

51. Wanhainen A, Mani K, Vorkapic E, De Basso R, Björck M, Länne T, et al. Screening of circulating microRNA biomarkers for prevalence of abdominal aortic aneurysm and aneurysm growth. Atherosclerosis. 2017;256: 82–88. doi: 10.1016/j.atherosclerosis.2016.11.007 27993388

Článek vyšel v časopise


2019 Číslo 9

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Zvyšte si kvalifikaci online z pohodlí domova

Výhody léčby pacientů s DM 2. typu GLP-1 agonisty
nový kurz
Autoři: prof. MUDr. Martin Haluzík, DrSc.

Syndrom suchého oka – diagnostika, komplikace a léčba
Autoři: MUDr. Petr Výborný, CSc., FEBO

Systémová léčba psoriázy
Autoři: MUDr. Jiří Horažďovský, Ph.D

Klinická farmakokinetika betablokátorů

Současné možnosti terapie osteoartrózy
Autoři: MUDr. Jakub Holešovský

Všechny kurzy